NASDAQ · LLY
Healthcare · Drug Manufacturers - General
$1,136.11
Down-$1.30 (-0.11%)
Updated Sep 16, 2026, 11:09 AM
SID Score
5.8/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LLY closed at $1,136.11 after 20 trading sessions, down 7.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
| Sep 14, 2026 | $1,142.20 | $1,153.95 | $1,130.5001 | $1,138.28 | 2.13M |
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
| Sep 9, 2026 | $1,127.61 | $1,138.79 | $1,119.00 | $1,124.21 | 2.05M |
| Sep 8, 2026 | $1,133.00 | $1,134.53 | $1,113.55 | $1,123.91 | 2.4M |
| Sep 4, 2026 | $1,150.61 | $1,158.44 | $1,138.306 | $1,149.36 | 2.22M |
| Sep 3, 2026 | $1,170.00 | $1,171.66 | $1,137.50 | $1,159.60 | 2.55M |
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
| Aug 21, 2026 | $1,232.00 | $1,271.22 | $1,230.00 | $1,255.40 | 2.5M |
| Aug 20, 2026 | $1,274.13 | $1,280.28 | $1,243.2301 | $1,244.40 | 2.62M |
| Aug 19, 2026 | $1,245.81 | $1,292.65 | $1,240.54 | $1,280.34 | 4.54M |
| Aug 18, 2026 | $1,200.00 | $1,228.47 | $1,194.01 | $1,225.73 | 2.51M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Reduce | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Citigroup | Buy | — |
Generated Sep 15, 2026, 9:18 PM
Eli Lilly shares are essentially flat, down just 0.11%, as investors digest a wave of bullish analyst upgrades offset by intensifying competitive pressures in the obesity drug market. The mixed sentiment reflects growing confidence in LLY's pipeline while acknowledging headwinds from Novo Nordisk's strategic repositioning and broader market adoption challenges.
Bottom line: Eli Lilly is caught between compelling long-term fundamentals—validated by high-profile analyst upgrades and strong commercial traction in oral weight-loss drugs—and near-term execution uncertainties in a rapidly evolving competitive landscape. Investors should monitor upcoming European data presentations closely, while remaining cognizant of pricing pressures and market adoption risks as multiple players expand into adjacent GLP-1 applications.
Yahoo · Sep 16, 2026
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Yahoo · Sep 15, 2026
One fast-growing business could push results above guidance
Yahoo · Sep 15, 2026
The drugmaker has a lot riding on continued clinical progress.
Yahoo · Sep 15, 2026
Thatch, the health benefits platform helping employers move from traditional group health plans to a consumer-directed model, today announced that it has raised $108 million in new funding at a $1 billion valuation from The General Partnership, Index Ventures, General Catalyst, and Andreessen Horowitz, with participation from ADP Ventures, Paychex, Eli Lilly and Company, Scale Venture Partners, QuantumLight, SemperVirens, Quiet Capital, and Avid Ventures.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,136.98, reflecting a single-session decline of 1.66%, per SID market data. Over the trailing one-month period, LLY has declined 5.85%, though the stock remains up 14.56% over the past twelve months, demonstrating sustained longer-term strength. The three-month return stands at a modest 0.47%, indicating a period of consolidation. Technically, LLY trades below its 50-day moving average of $1,183.14 but well above its 200-day moving average of $1,060.24, according to Massive/Polygon data. The 14-day relative strength index registers at 16.3, placing the stock firmly in oversold territory and suggesting recent selling pressure has been pronounced. LLY carries a beta of 0.369, indicating significantly lower volatility than the broader market. Average daily trading volume stands at approximately 3.80 million shares, supporting a market capitalization of roughly $906.5 billion.
Eli Lilly and Company currently trades at a price-to-earnings ratio of 49.16, reflecting a substantial premium relative to broader market averages and the Healthcare sector, per SID market data. The PEG ratio stands at 1.47, according to SEC filings, suggesting the valuation is modestly above the commonly referenced fair-value threshold of 1.0 but remains within a range that accounts for the company's elevated earnings growth trajectory. The price-to-book ratio of 38.04 underscores the market's significant premium assigned to Eli Lilly's intangible assets, including its GLP-1 receptor agonist franchise and broader pipeline. The company maintains a dividend yield of approximately 0.59%, a relatively modest payout consistent with a growth-oriented large-cap pharmaceutical firm prioritizing reinvestment in research and development. Collectively, these metrics position LLY as a premium-valued Healthcare name where growth expectations are priced meaningfully above sector norms.
Eli Lilly and Company's composite smart money score stands at 46 out of 100, generating a neutral signal, per SID market data. Institutional positioning is the strongest component, scoring a perfect 25 out of 25, indicating robust conviction among major asset managers and fund complexes based on 13F institutional filings. In contrast, the insider trading score registers at just 4.1 out of 25, despite relatively balanced activity: SEC Form 4 filings reveal nine insider transactions over the past 90 days, comprising five purchases and four sales. The dark pool activity score of 9.2 out of 25 suggests moderate but not aggressive off-exchange accumulation. Congressional trading activity scores 7.6 out of 25, reflecting limited notable positioning by members of Congress. The divergence between exceptionally strong institutional ownership signals and weaker insider and dark pool metrics explains the overall neutral composite reading, indicating no clear directional bias from sophisticated market participants at current price levels.
Eli Lilly and Company has delivered a consistent pattern of earnings outperformance across recent quarters, per company earnings reports. In the most recently reported quarter, the company posted earnings per share of $8.55 against analyst estimates of $6.85, representing a positive surprise of $1.70. The prior quarter showed even stronger outperformance, with actual EPS of $8.38 versus estimates of $6.01, a beat of $2.37. The quarter before that also exceeded expectations, reporting $7.54 against a $6.96 consensus for a $0.58 surprise. Looking ahead, analyst estimates project EPS of $8.84 for the upcoming quarter with results expected on August 6, 2026. The progressive increase in both actual earnings and consensus estimates reflects the company's accelerating revenue growth profile. The three consecutive beats, averaging approximately $1.55 per share above consensus, suggest systematic underestimation of Eli Lilly's earnings power by the analyst community.
Wall Street consensus on Eli Lilly and Company remains predominantly bullish, per SID consensus data. Among the most recent analyst actions, Truist Securities reiterated a Buy rating on August 7, 2026, while both Wells Fargo and Cantor Fitzgerald maintained Overweight ratings on August 6, 2026, following the company's earnings release, according to Wall Street analyst reports. Citigroup also reiterated its Buy rating on July 15, 2026. The sole dissenting voice among recent coverage comes from HSBC, which maintained a Reduce rating on September 10, 2026, representing a contrarian stance against the broader consensus. Of the five most recent analyst actions tracked, four carry bullish or overweight designations while one maintains a bearish posture, translating to an 80% positive rating ratio. Notably, none of these recent actions involved rating changes, suggesting analysts remain firmly entrenched in their respective positions on LLY's outlook following a period of strong fundamental execution.
The latest Smart Investors Daily articles mentioning LLY.
